Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial

American Heart Journal
John J V McMurrayCHARM Investigators

Abstract

Whether an angiotensin receptor blocker is of benefit when added to a full dose of angiotensin-converting enzyme (ACE) inhibitor in heart failure (HF) is uncertain. The effect of candesartan, compared with placebo, in 2548 patients randomized in the CHARM-Added trial was analyzed according to (i) ACE inhibitor dose at baseline, (ii) ACE inhibitor dose during follow-up, and (iii) combination treatment with ACE inhibitor and beta-blocker at baseline. The main outcome was the composite of cardiovascular death or HF hospitalization. The benefit of candesartan was not modified by the dose of ACE inhibitor. In all patients (n = 2548), the candesartan/placebo hazard ratio (HR) for the primary outcome was 0.85 (95% CI 0.75-0.96). In patients taking a guideline recommended dose of ACE inhibitor at baseline (n = 1291), this HR was 0.79 (95% CI 0.67-0.95; interaction P value .26). In patients taking a Food and Drug Administration-designated maximum dose of ACE inhibitor (n = 529), this HR was 0.75 (95% CI 0.57-0.98; interaction P value .29). The benefit of candesartan was preserved in patients taking beta-blockers in addition to a higher dose of ACE inhibitor and in patients maintaining a high dose of ACE inhibitor throughout follow-up. T...Continue Reading

References

Aug 1, 1991·The New England Journal of Medicine·UNKNOWN SOLVD InvestigatorsJay N Cohn
Aug 9, 2001·European Heart Journal·W J RemmeUNKNOWN Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology

❮ Previous
Next ❯

Citations

Aug 18, 2006·Cardiovascular Drugs and Therapy·Aldo P Maggioni
Jun 27, 2009·Archives of Pharmacal Research·Chang-Yong ShinChang-Seon Myung
Apr 2, 2008·The New England Journal of Medicine·John J V McMurray
Sep 1, 2009·European Heart Journal·Aldo P MaggioniUNKNOWN GISSI-HF Investigators
Sep 30, 2010·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·A John CammUNKNOWN ESC Committee for Practice Guidelines
Jan 14, 2012·Circulation Journal : Official Journal of the Japanese Circulation Society·Ajith P NairValentin Fuster
Aug 24, 2012·Journal of Geriatric Cardiology : JGC·Elizabete Viana de FreitasRoberto Gamarsky
Feb 13, 2014·Herzschrittmachertherapie & Elektrophysiologie·Andreas GoetteAlicja Bukowska
Oct 30, 2009·Current Cardiology Reports·Orson Go, Clive Rosendorff
Sep 25, 2010·La Revue de médecine interne·F ArnoultG Jondeau
Mar 27, 2007·Pharmacotherapy·Mark E Dunlap
Jul 28, 2011·European Journal of Heart Failure·Richard LowrieJohn J V McMurray
Sep 8, 2011·The Journal of Clinical Hypertension·Joseph L Izzo, Matthew R Weir
Mar 31, 2009·European Journal of Internal Medicine·B SolunD Dicker
Oct 6, 2006·Expert Opinion on Pharmacotherapy·Robert S McKelvie
Nov 13, 2007·Journal of the American College of Cardiology·Akshay S DesaiUNKNOWN CHARM Program Investigators
Apr 25, 2016·JACC. Heart Failure·Milton Packer
Jun 15, 2007·Journal of Cardiovascular Pharmacology and Therapeutics·Charles H HennekensKarl Swedberg
Jan 26, 2018·Cardiology in Review·Sabrina Bernardez-PereiraAntonio Carlos Pereira-Barretto
Dec 25, 2008·Expert Review of Cardiovascular Therapy·Robert S McKelvie
Feb 28, 2020·The Cochrane Database of Systematic Reviews·Meaghan LunneyPietro Ravani
May 31, 2019·Current Heart Failure Reports·Clara Stegmann, Gerhard Hindricks
Mar 16, 2007·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Maya GuglinHema Vankayala
Jan 19, 2021·European Journal of Heart Failure·Maurizio VolterraniUNKNOWN on the behalf of a LHUs Study Group (see Appendix)

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.